- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Dynamic Healthcare launches clinical ASP for hospitals, docs
Dynamic Healthcare launches clinical ASP for hospitals, docsDynamic Healthcare Technologies has introduced CoMed, a suite of clinical connectivity and application services for physicians, hospitals, and ambulatory clinics. CoMed, for
Dynamic Healthcare launches clinical ASP for hospitals, docs
Dynamic Healthcare Technologies has introduced CoMed, a suite of clinical connectivity and application services for physicians, hospitals, and ambulatory clinics. CoMed, for collaborative medicine, is designed to enhance the capture and dissemination of clinical and diagnostic information in any form and enable anywhere/anytime access by physicians and other healthcare providers across the enterprise. Specific capabilities offered through CoMed include access to pathology and radiology reports and images, voice recognition for transcription and dictation of clinical interpretations, access to online medical references and news, and collaboration with colleagues during the diagnostic process. Dynamic plans to manage, host, and deliver CoMed as a subscription service.
- Search Again
- Return To HNN Homepage
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
